These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 31375917)
1. Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H Heart Vessels; 2019 Nov; 34(11):1852-1857. PubMed ID: 31375917 [TBL] [Abstract][Full Text] [Related]
2. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325 [TBL] [Abstract][Full Text] [Related]
3. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study. Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999 [TBL] [Abstract][Full Text] [Related]
5. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. Shimokawa H; Yamashita T; Uchiyama S; Kitazono T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Atarashi H; Inoue H Int J Cardiol; 2018 May; 258():126-132. PubMed ID: 29429636 [TBL] [Abstract][Full Text] [Related]
6. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338 [TBL] [Abstract][Full Text] [Related]
7. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. Coleman CI; Bunz TJ; Eriksson D; Meinecke AK; Sood NA Diabet Med; 2018 Aug; 35(8):1105-1110. PubMed ID: 29663521 [TBL] [Abstract][Full Text] [Related]
9. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. Amin A; Keshishian A; Vo L; Zhang Q; Dina O; Patel C; Odell K; Trocio J J Med Econ; 2018 Mar; 21(3):244-253. PubMed ID: 29047304 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Jones WS; Hellkamp AS; Halperin J; Piccini JP; Breithardt G; Singer DE; Fox KA; Hankey GJ; Mahaffey KW; Califf RM; Patel MR Eur Heart J; 2014 Jan; 35(4):242-9. PubMed ID: 24302273 [TBL] [Abstract][Full Text] [Related]
11. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. Ikeda T; Atarashi H; Inoue H; Uchiyama S; Kitazono T; Yamashita T; Shimizu W; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Shimokawa H Tohoku J Exp Med; 2016 Dec; 240(4):259-268. PubMed ID: 27904005 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424 [TBL] [Abstract][Full Text] [Related]
13. [Rivaroxaban at Non-Valvular Atrial Fibrillation: a Prospective Study and Clinical Practice]. Fonyakin AV Kardiologiia; 2016 Aug; 56(8):87-92. PubMed ID: 28290887 [TBL] [Abstract][Full Text] [Related]
14. [Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience]. Málek F Vnitr Lek; 2016; 62(10):814-819. PubMed ID: 27900868 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. Peng S; Deger KA; Ustyugova A; Gandhi P; Qiao N; Wang C; Kansal AR Curr Med Res Opin; 2018 Jan; 34(1):55-63. PubMed ID: 28862479 [TBL] [Abstract][Full Text] [Related]
16. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iwashiro S; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S J Thromb Thrombolysis; 2019 Nov; 48(4):653-660. PubMed ID: 31432451 [TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560 [TBL] [Abstract][Full Text] [Related]